Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central nervous method, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabilit... https://katherinei653jlr6.wikilima.com/user